Skip to main content

Table 3 Prescription rates: within-group changes over time

From: Effectiveness of confidential reports to physicians on their prescribing of antipsychotic medications in nursing homes

Time

Did not sign up, n = 707

Signed up but did not view, n = 78

Signed up and viewed report, n = 132

Mean percentage of nursing home days on antipsychotics

 Baseline

25.8

26.3

25.0

 3 months

25.4

25.6

24.1

 6 months

24.9

24.9

23.2

 Within-group changes over time (p value)

< 0.0001

< 0.0001

< 0.0001

 Change from baseline to 3 months: adjusted least square mean (95% CI)

− 0.41 (− 0.61, − 0.22)

− 0.72 (− 1.14, − 0.30)

− 0.89 (− 1.29, − 0.48)

 Change from baseline to 6 months: adjusted least square mean (95% CI)

− 0.88 (− 1.14, − 0.62)

− 1.35 (− 1.93, − 0.77)

− 1.82 (− 2.37, − 1.27)

Mean percentage of nursing home days on benzodiazepines^

 Baseline

10.5

9.8

10.2

 3 months

10.4

9.6

10.0

 6 months

10.3

9.7

9.7

 Within-group changes over time (p value)

0.001

0.387

0.001

 Change from baseline to 3 months: adjusted least square mean (95% CI)

− 0.10 (− 0.21, 0.02)

− 0.18 (− 0.45, 0.08)

− 0.16 (− 0.41, 0.09)

 Change from baseline to 3 months: adjusted least square mean (95% CI)

− 0.25 (− 0.38, − 0.12)

− 0.12 (− 0.41, 0.17)

− 0.52 (− 0.80, − 0.25)

Mean percentage of nursing home days on statins

 Baseline

17.5

16.4

16.5

 3 months

16.9

15.8

15.8

 6 months

16.2

15.2

15.0

 Within-group changes over time (p value)

< 0.0001

< 0.0001

< 0.0001

 Change from baseline to 3 months: adjusted least square mean (95% CI)

− 0.54 (− 0.64, − 0.44)

− 0.54 (− 0.76, − 0.32)

− 0.61 (− 0.82, − 0.40)

 Change from baseline to 3 months: adjusted least square mean (95% CI)

− 1.20 (− 1.35, − 1.05)

− 1.17 (− 1.51, − 0.84)

− 1.44 (− 1.76, − 1.12)

  1. Multivariable linear mixed effects regression adjusted for the following: nursing home variables (number of beds, urban vs. rural location, private vs. public institution), physician variables (sex, age [cont.], years practicing [cont.], Canadian vs. foreign graduate, number of nursing home residents [cont.], number of nursing home institutions practicing in [cont.], percent of billings in nursing homes), and resident characteristics (sex, age [cont.] time in nursing home [cont.], Charlson comorbidity scale [cont.], diabetes, hypertension, arteriosclerotic heart disease, heart failure, peripheral vascular disease, deep vein thrombosis, cardiac dysrhythmia, Alzheimer’s, dementia, cancer, obstructive airway disease, depression, arthritis, Parkinson’s disease, activities of daily living scale, pain score, depression rating scale, likelihood of falls scale, aggressive behavior scale, frailty index, emergency room visits in past year [cont.], inpatient hospitalizations in past year [cont.], any psychiatric consult in past year, any geriatric consult in past year, any benzodiazepine use). Analyses restricted to physicians who signed up in time for the initial release of the intervention
  2. ^Any benzodiazepine use dropped from adjustment in this model